Top Medical News
Stephen Padilla, 2 days ago
Nocturia, or waking from sleep two or more times at night to void, appears to slightly increase the risk of mortality, results of a systematic review and meta-analysis have shown.
4 days ago
An association exists between the development of metabolic acidosis following ileal neobladder construction and continuous improvement of urinary continence in the early recovery period, reveals a recent study.
5 days ago
The clinical and microbiological effectiveness of a single dose of oral fosfomycin trometamol is comparable to that of comparator antibiotics, as is safety, in women with confirmed or suspected acute uncomplicated cystitis, a recent study has shown. Use of fosfomycin trometamol is also associated with high patient compliance.
Audrey Abella, 5 days ago
Increasing vegetable consumption did not significantly reduce the risk of prostate cancer progression in men with early-stage disease on active surveillance, the MEAL* trial shows, which contradicts clinical guidelines recommending a vegetable-rich diet in this patient setting.
06 Feb 2020
Paediatric patients with neurogenic bladder may benefit from intradetrusor abobotulinum toxin A, which has been shown to improve cystometric capacity and maximum neurogenic detrusor overactivity in a recent study. This effect persists over multiple injections.
Jairia Dela Cruz, 06 Feb 2020
The combination of piperacillin plus tazobactam performs well in the management of nonbacteraemic pyelonephritis caused by extended-spectrum β-lactamase (ESBL)-producing organisms, with rates of symptom resolution and 30-day mortality similar to that achieved with carbapenem, as shown in a recent study.
05 Feb 2020
Use of mid-urethral tension-free vaginal tape slings leads to better satisfaction and cure rates in women with primary stress urinary incontinence compared with polyacrylamide hydrogel injection, according to a study. However, complication risks are higher with tension-free vaginal tape.
Special Reports
26 Nov 2019
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.
15 Mar 2019
At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.
Conference Reports
Pank Jit Sin, 03 Sep 2019

Immunotherapy, in the setting of advanced prostate cancer (PCa), may alter the lethal condition of advanced PCa into a chronic disease with significantly longer overall survival (OS), says an expert. 
Jackey Suen, 06 Mar 2019

The future of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC) is promising in light of encouraging results from recent clinical studies.

Dr. Joseph Delano Fule Robles, 04 Mar 2019

Since the approval of immune checkpoint inhibitors (ICIs) as standard of care in the second-line setting for metastatic urothelial carcinoma, new approaches on how clinicians manage this condition are emerging.

Dr. Joseph Delano Fule Robles, 22 Feb 2019

Studies have demonstrated that robot-assisted radical cystectomy (RARC) is as effective and has a cost advantage compared with open cystectomy for the management of urologic cancers.

Jackey Suen, 30 Jan 2019

Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.

Audrey Abella, 11 May 2018
Nanotechnology structured water was similarly effective as tadalafil in improving erectile function, suggesting that it could be a potential treatment option for erectile dysfunction (ED), according to a study presented at EAU held in Copenhagen, Denmark.
Audrey Abella, 30 Apr 2018
The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.